Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

- Men and women with ages between 18 and 70 years old, inclusive. - Protocol-defined elevated plasma Lp(a) level. - Body mass index (BMI) greater than or equal to 18 and less than or equal to 40 kg/m2, at screening. - Women must be of non-reproductive potential. - Other Inclusion criteria may apply

- Currently receiving treatment in another investigational device or drug study. - Women who are lactating/breastfeeding or who plan to breastfeed while on study or through 90 days after receiving the last dose of investigational product (for subjects who withdraw prior to end of study). - History or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. - History or clinical evidence of bleeding diathesis or any coagulation disorder. - History or clinical evidence of peripheral neuropathy. - Other Exclusion criteria may apply